NEW YORK (GenomeWeb) – MDxHealth reported today that its third quarter revenues rose 122 percent, driven by a sharp increase in the number of payors issuing positive coverage decisions for its ConfirmMDx and SelectMDx prostate cancer tests.

For the three months ended Sept. 30, the Belgian molecular diagnostics company said revenues rose to $9.1 million from $4.1 million in Q3 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.